IT HAS ALREADY BEEN A EVENTFUL WEEK FOR NASDAQ:TNXP WITH CAPITAL RAISE ISSUES AND A NEW PIPELINE DRUG CANDIDATE UPDATE. NEST WEEK COULD BE EQUALLY IMPORTANT AS ON TUESDAY THE COMPANY RELEASES DATA ON TNX-102 PHARMACOKINTEC . THE STOCK IS SETTING UP NICELY FOR THE WEEK TO COME.
COMPANY PROFILE
Tonix Pharmaceuticals Holding Corp. is a clinical-stage...
Possible Buy opportunity in TNXP .
The stock has set itself up for a perfect W-PATTERN .
This is used by market makers to grab the as much money from the bottom of
a rising stock.
The stock also has several catalyst .
Plus it has Strong support on the 100 moving AVERAGE.
Take A look .
Don't miss out on making money!!!
Chart looks primed to run.. PT 2.8-3.4
Golden Cross on hourly next week probably
MACD right* below 0 trending upwards on Daily (+ Divergence)
LOW Float 1.4M
Announce $2 buyback.. what % of float is that?
Price crossed 50 and 200 2 times and closed above 50 and 200 on hourly.
FDA Rescinded "breakthrough" doesn't change NDA or phase 3...
TNXP - Recent 8K filed 10/2 - presenting / PR
Trending up making higher lows. buyers stepping in. Might start to run.
Short Float 6% finviz.com
Swing Idea:
Buy between red and orange line.. stop loss at.58.
Take profits (scale out at green line or if there is news and volume increase)
Daytrade Idea:
Watch for PM volume...
The gap up out of accumulation seen here is quickly cancelled out by way of significant retracement, I could still this breaking out...but not before another period of accumulation at this new level. Time will tell.
COMPANY IS IN STAGE 2 OF A DRUG FOR PTSD SO i AM LOADING UP ON IT IN THE EVENT THE FDA APPROVES THE DRUG
ALSO TO ME THEIR ASSETS EXCEEDS THEIR LIABILITIES MEANING THEY'RE ABLE TO PAY THEIR BILLS
Earnings reported on 8.05 caused a positive movement to 2.73, TNXP had a large down day on 9.02 reaching the pre earnings price level then closing higher to a prior resistance level. If the prior resistance level that was established pre earnings can be broken, with positive momentum the price may return to the earnings positive prices. If not further movement...
Ticker gaining positive sentiment over the weekend. FDA approval expected in Sept. after previously submitted positive Phase 3 results. Current PPS shows minimum R/R Ratio of 2.71. Will be looking to open half position swing entry at $2.20 and completing fill > $2.90.
Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company. The Company's drug development programs are directed toward disorders affecting the central nervous system (CNS), and include fibromyalgia (FM), and post-traumatic stress disorder (PTSD). It is focused on developing a portfolio of product candidates, including one product candidate in clinical development for registration in two indications. TNX-102 SL (cyclobenzaprine hydrochloric acid (HCl) sublingual tablets), is a disintegrating tablet containing cyclobenzaprine (CBP) for sublingual administration. The Company has completed Phase IIb BESTFIT trial of TNX-102 SL for fibromyalgia. It is being evaluated in the Phase III AFFIRM study for the treatment of fibromyalgia. The Company is also conducting AtEase trial, which is a Phase II clinical trial of TNX-102 SL in military-related PTSD. It also has a pipeline of other product candidates, including TNX-301, a fixed dose combination drug product (CDP).
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
TNXP
